Immune dysregulation in sepsis: experiences, lessons and perspectives

被引:76
作者
Cao, Min [1 ]
Wang, Guozheng [2 ,3 ]
Xie, Jianfeng [1 ]
机构
[1] Southeast Univ, Zhongda Hosp, Sch Med, Dept Crit Care Med,Jiangsu Prov Key Lab Crit Care, Nanjing, Peoples R China
[2] Univ Liverpool, Dept Clin Infect Microbiol & Immunol, Liverpool L69 7BE, England
[3] Liverpool Univ Hosp NHS Fdn Trust, Coagulat, Liverpool L7 8XP, England
基金
中国国家自然科学基金;
关键词
COLONY-STIMULATING FACTOR; VENTILATOR-ASSOCIATED PNEUMONIA; FACTOR ANTIBODY-FRAGMENT; PLACEBO-CONTROLLED TRIAL; SEPTIC SHOCK; DOUBLE-BLIND; IN-VIVO; GLUCOCORTICOID THERAPY; INFLAMMATORY RESPONSE; IMPROVES SURVIVAL;
D O I
10.1038/s41420-023-01766-7
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Sepsis is a life-threatening organ dysfunction syndrome caused by dysregulated host responses to infection. Not only does sepsis pose a serious hazard to human health, but it also imposes a substantial economic burden on the healthcare system. The cornerstones of current treatment for sepsis remain source control, fluid resuscitation, and rapid administration of antibiotics, etc. To date, no drugs have been approved for treating sepsis, and most clinical trials of potential therapies have failed to reduce mortality. The immune response caused by the pathogen is complex, resulting in a dysregulated innate and adaptive immune response that, if not promptly controlled, can lead to excessive inflammation, immunosuppression, and failure to re-establish immune homeostasis. The impaired immune response in patients with sepsis and the potential immunotherapy to modulate the immune response causing excessive inflammation or enhancing immunity suggest the importance of demonstrating individualized therapy. Here, we review the immune dysfunction caused by sepsis, where immune cell production, effector cell function, and survival are directly affected during sepsis. In addition, we discuss potential immunotherapy in septic patients and highlight the need for precise treatment according to clinical and immune stratification.
引用
收藏
页数:11
相关论文
共 143 条
[1]   Molecular Mechanisms Underlying IL-33-Mediated Inflammation in Inflammatory Bowel Disease [J].
Aggeletopoulou, Ioanna ;
Tsounis, Efthymios P. P. ;
Triantos, Christos .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (01)
[2]   Efficacy of Intravenous Immunoglobulin Therapy for Patients With Sepsis and Low Immunoglobulin G Levels: A Single-Center Retrospective Study [J].
Akatsuka, Masayuki ;
Masuda, Yoshiki ;
Tatsumi, Hiroomi ;
Sonoda, Tomoko .
CLINICAL THERAPEUTICS, 2022, 44 (02) :295-303
[3]   Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection [J].
Alves-Filho, Jose C. ;
Sonego, Fabiane ;
Souto, Fabricio O. ;
Freitas, Andressa ;
Verri, Waldiceu A., Jr. ;
Auxiliadora-Martins, Maria ;
Basile-Filho, Anibal ;
McKenzie, Andrew N. ;
Xu, Damo ;
Cunha, Fernando Q. ;
Liew, Foo Y. .
NATURE MEDICINE, 2010, 16 (06) :708-U113
[4]   Deficit of interleukin 7 in septic patients [J].
Andreu-Ballester, Juan C. ;
Cuellar, Carmen ;
Garcia-Ballesteros, Carlos ;
Perez-Griera, Jaime ;
Amigo, Victoria ;
Peiro-Gomez, Ana ;
Penarroja-Otero, Carlos ;
Ballester, Ferran ;
Mayans, Jose ;
Tormo-Calandin, Constantino .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2014, 23 (01) :73-76
[5]   Hydrocortisone plus Fludrocortisone for Adults with Septic Shock [J].
Annane, D. ;
Renault, A. ;
Brun-Buisson, C. ;
Megarbane, B. ;
Quenot, J. -P. ;
Siami, S. ;
Cariou, A. ;
Forceville, X. ;
Schwebel, C. ;
Martin, C. ;
Timsit, J. -F. ;
Misset, B. ;
Benali, M. Ali ;
Colin, G. ;
Souweine, B. ;
Asehnoune, K. ;
Mercier, E. ;
Chimot, L. ;
Charpentier, C. ;
Francois, B. ;
Boulain, T. ;
Petitpas, F. ;
Constantin, J. -M. ;
Dhonneur, G. ;
Baudin, F. ;
Combes, A. ;
Bohe, J. ;
Loriferne, J. -F. ;
Amathieu, R. ;
Cook, F. ;
Slama, M. ;
Leroy, O. ;
Capellier, G. ;
Dargent, A. ;
Hissem, T. ;
Maxime, V. ;
Bellissant, E. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (09) :809-818
[6]   Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock [J].
Annane, D ;
Sébille, V ;
Charpentier, C ;
Bollaert, PE ;
François, B ;
Korach, JM ;
Capellier, G ;
Cohen, Y ;
Azoulay, E ;
Troché, G ;
Chaumet-Riffaut, P ;
Bellissant, E .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (07) :862-871
[7]   Transcriptomic Signatures in Sepsis and a Differential Response to Steroids From the VANISH Randomized Trial [J].
Antcliffe, David B. ;
Burnham, Katie L. ;
Al-Beidh, Farah ;
Santhakumaran, Shalini ;
Brett, Stephen J. ;
Hinds, Charles J. ;
Ashby, Deborah ;
Knight, Julian C. ;
Gordon, Anthony C. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199 (08) :980-986
[8]   Pathophysiology of sepsis [J].
Arina, Pietro ;
Singer, Mervyn .
CURRENT OPINION IN ANESTHESIOLOGY, 2021, 34 (02) :77-84
[9]   IL-33 receptor (ST2) deficiency downregulates myeloid precursors, inflammatory NK and dendritic cells in early phase of sepsis [J].
Babic, Zivan M. ;
Zunic, Filip Z. ;
Pantic, Jelena M. ;
Radosavljevic, Gordana D. ;
Jovanovic, Ivan P. ;
Arsenijevic, Nebojsa N. ;
Lukic, Miodrag L. .
JOURNAL OF BIOMEDICAL SCIENCE, 2018, 25
[10]   Predicting sepsis severity at first clinical presentation: The role of endotypes and mechanistic signatures [J].
Baghela, Arjun ;
Pena, Olga M. ;
Lee, Amy H. ;
Baquir, Beverlie ;
Falsafi, Reza ;
An, Andy ;
Farmer, Susan W. ;
Hurlburt, Andrew ;
Mondragon-Cardona, Alvaro ;
Rivera, Juan Diego ;
Baker, Andrew ;
Trahtemberg, Uriel ;
Shojaei, Maryam ;
Jimenez-Canizales, Carlos Eduardo ;
dos Santos, Claudia C. ;
Tang, Benjamin ;
Bouma, Hjalmar R. ;
Freue, Gabriela V. Cohen ;
Hancock, Robert E. W. .
EBIOMEDICINE, 2022, 75